Analysis Of Cardiovascular Risk Stratification And Achievement Of LDL-Cholesterol Therapeutic Goals In A University Endocrinology Outpatient Clinic In Belo Horizonte

Abstract

Introduction: Dyslipidemia is an important modifiable risk factor for cardiovascular diseases, with statins being the main drug therapy used to reduce LDL levels. However, regarding the use of lipid-lowering drugs, the majority of individuals do not reach the stipulated therapeutic goal and many are associated with other cardiometabolic comorbidities, such as diabetes and overweight/obesity, being followed up through endocrinology outpatient clinic. Objective: Identify the clinical and epidemiological profile of patients using statins at a university outpatient clinic in Belo Horizonte and evaluate the degree of dyslipidemia control based on cardiovascular risk. Method: Retrospective cross--sectional study, approved by the Ethics and Research Committee, based on the analysis of medical records of dyslipidemic patients using statins, followed up at the endocrinology outpatient clinic in 2022. Patients with unlocated and/or incomplete medical records were excluded. Results: 42 individuals were included, 83% were female, median age of 65 years. Regarding cardiovascular risk, 4 (9%) were very high, 33 (78%) high, 4 (9%) intermediate and 1 (4%) was low. The main LDL levels were 86±42 mg/dl. Among the statins used, it was observed that 29 (69%) used simvastatin, 9 (21%) atorvastatin and 4 (10%) rosuvastatin. It was observed that 29 (69%) individuals were outside the therapeutic target according to their cardiovascular risk targets and, of these, 17 (59%) were using Simvastatin. Conclusion: The prescription of statins on an outpatient basis is widespread, however a few patients have LDL levels within the therapeutic target established by cardiovascular risk.